Related Experiment Video
Updated: Jul 17, 2026
09:30
Microbial Control and Monitoring Strategies for Cleanroom Environments and Cellular Therapies
Published on: March 17, 2023
Changes in the state operations manual: implications for consultant pharmacy practice.
Caren McHenry Martin1, Carla Saxton McSpadden
1Greensboro, North Carolina, USA.
Summary
New regulations from the Centers for Medicare and Medicaid Services will increase accountability for consultant pharmacists in long-term care facilities regarding medication use during annual reviews.
Area of Science:
- Pharmacy Practice
- Healthcare Regulation
- Geriatric Medicine
Background:
- Long-term care facilities undergo annual surveys by federal regulators.
- The Centers for Medicare and Medicaid Services (CMS) sets the standards for these reviews.
- Current regulations guide surveyor actions and facility compliance.
Purpose of the Study:
- To highlight recent revisions to the State Operations Manual.
- To inform stakeholders about impending changes in accountability for consultant pharmacists.
- To emphasize the impact of regulatory updates on medication management in long-term care.
Main Methods:
- Analysis of updated State Operations Manual guidance.
- Review of Centers for Medicare and Medicaid Services regulations.
- Examination of surveyor protocols for long-term care facilities.
Main Results:
- Revisions to the State Operations Manual introduce new accountability measures.
- Consultant pharmacists face heightened scrutiny regarding medication use.
- Surveyors' guidance reflects an increased focus on medication management oversight.
Conclusions:
- The updated manual signifies a shift in regulatory expectations for consultant pharmacists.
- Enhanced accountability aims to improve medication safety and efficacy in long-term care.
- Facilities and pharmacists must adapt to new compliance requirements to ensure quality care.
Related Concept Videos
01:26FDA Approved Drugs: Changes to Approved Drugs
Post-approval, manufacturers may modify an approved new or generic drug product. Such modifications can encompass alterations in the Active Pharmaceutical Ingredient (API), manufacturing process, formulation, batch size, manufacturing site, and container closure system (FDA Guidance for Industry, April 2004). Often, a drug product may undergo multiple changes.These modifications require careful evaluation to determine their potential impact on the drug product's identity, strength, quality,...
01:15Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions
PK–PD modeling has significantly influenced FDA regulatory decisions, particularly drug approval, dosage optimization, and labeling. These models integrate pharmacokinetics (PK) and pharmacodynamics (PD) to predict drug behavior and effects, aiding in optimizing dosing regimens and enhancing the probability of clinical trial success.One notable example is Nesiritide (Natrecor®), a recombinant human brain natriuretic peptide for treating acute decompensated congestive heart failure (CHF).
01:28Dosage Regimens: Designs and Approaches
Designing a dosage regimen, which refers to the manner of drug administration, is a complex process involving the selection of drug dose, route, and frequency. This process is underpinned by pharmacokinetic parameters derived from tests and population averages. These parameters are then tailored to patient-specific variables such as diagnosis, demographics, and allergy status. Once therapy commences, therapeutic response monitoring is critical and achieved through clinical and physical...
01:27Pharmaceutical Alternatives: Polymorphic Form-Related and Particle Size-Related Therapeutic Nonequivalence
Changes in polymorphic forms can significantly influence the bioavailability of poorly soluble drugs. Although the FDA defines pharmaceutical equivalence based on having the same active ingredient, dosage form, and route of administration, it does not automatically disqualify products with different polymorphic forms. This means two products with different polymorphs can still be deemed pharmaceutically equivalent. However, polymorphic differences can affect properties like wettability,...
00:59Model-Independent Approaches for Pharmacokinetic Data: Noncompartmental Analysis
Noncompartmental analyses offer an alternative method for describing drug pharmacokinetics without relying on a specific compartmental model. In this approach, the drug's pharmacokinetics are assumed to be linear, with the terminal phase log-linear. This assumption allows for simplified analysis and interpretation of the drug's behavior in the body.
One important characteristic of noncompartmental analyses is that drug exposure increases proportionally with increasing doses. This relationship...
One important characteristic of noncompartmental analyses is that drug exposure increases proportionally with increasing doses. This relationship...
01:26Pharmaceutical Poisoning: Potential Scenarios
Pharmaceutical poisoning can occur through various channels, impacting an estimated 2 million hospitalized patients in the U.S. annually with serious adverse drug responses. These scenarios encompass both therapeutic uses, such as drug toxicity, where even standard dosages can lead to severe central nervous system depression, and non-therapeutic exposures, including accidental ingestion by children, and environmental and occupational exposures.Unintentional poisonings often involve exploratory...